IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.08
−1.34%Year over year
Reported trailing growth
- Revenue
- +192.9%
- EBITDA
- —
- EBIT
- +11.8%
- EPS
- —
- Free cash flow
- -2.5%
- Operating cash flow
- -2.0%
Forward estimates
Based on analyst estimates
- Revenue
- +61.2%
- EBITDA
- +77.1%
- EPS
- +67.6%
Three-year CAGR
- Revenue
- +678.6%
- EBITDA
- +15.5%
- EBIT
- +25.6%
- Net income
- +15.0%
- EPS
- +35.6%
- Free cash flow
- +22.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026